Lumos announces new analyses of data from OraGrowtH210, OraGrowtH212 trials
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 21 2024
0mins
Should l Buy ?
Clinical Trial Updates: Lumos Pharma presented new analyses from its Phase 2 OraGrowtH210 and OraGrowtH212 trials at the ESPE 2024 meeting, showing sustained growth in children with moderate Pediatric Growth Hormone Deficiency (PGHD) after 24 months of treatment with LUM-201.
Future Plans: The company is optimistic about the results and plans to advance LUM-201 into a Phase 3 clinical trial for moderate PGHD next year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
